Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.
Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1-year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.
Operative Unit of Dermatology, 1st Medical Department, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. vito.dilernai@asmn.re.it
V
V
Di Lernia
C
C
Ricci
G
G
Albertini
D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002610:Cheek; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007636:Keratoacanthoma / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D012871:Skin Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod